RELIEF THERAPEUTICS N/ CH0100191136 /
| 2/3/2023 5:30:04 PM | Chg. -0.0002 | Volume | Bid6:30:14 AM | Ask6:30:14 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 0.0287CHF | -0.69% | 3.61 mill. Turnover: 103,043.6295 |
0.0295Bid Size: 5,000 | -Ask Size: 7,112 | 124.86 mill.CHF | - | - |
GlobeNewswire
3/7/2022
Acer Therapeutics Secures up to $48.5 Million in Convertible Note and Secured Loan Financing Facilit...
GlobeNewswire
3/2/2022
Acer Therapeutics Reports Q4 and Full Year 2021 Financial Results and Provides Corporate Update
GlobeNewswire
1/27/2022
Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upco...
GlobeNewswire
11/19/2021
Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update
GlobeNewswire
11/16/2021
NRx Pharmaceuticals Reports Third-Quarter 2021 Business Update and Financial Results
GlobeNewswire
10/26/2021
Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-...
GlobeNewswire
10/7/2021
Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Form...
GlobeNewswire
10/6/2021
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application...
GlobeNewswire
8/30/2021
Acer Therapeutics to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
GlobeNewswire
8/10/2021
Acer Therapeutics Reports Q2 2021 Financial Results and Provides Corporate Update
GlobeNewswire
8/9/2021
Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. ...
GlobeNewswire
6/10/2021
Acer Therapeutics Plans Clinical Trial for EDSIVO™ (celiprolol) Following Type B FDA Meeting
GlobeNewswire
5/25/2021
Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA
GlobeNewswire
5/17/2021
Acer Therapeutics Reports Q1 2021 Financial Results and Provides Corporate Update
GlobeNewswire
3/22/2021
Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and ...
GlobeNewswire
3/19/2021
UPDATE: NeuroRx Announces Dosing of First Patient with ZYESAMI™ in P2/3 Clinical Study for the Treat...
GlobeNewswire
3/19/2021
NeuroRx Announces Dosing of First Patient with ZYESAMI™ in P2/3 Clinical Study for the Treatment of ...
GlobeNewswire
3/1/2021
Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate...
GlobeNewswire
1/25/2021
Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Colla...
GlobeNewswire
7/16/2020
NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2...